Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment

By Reuters Staff

March 17, 2020

(Reuters) - Sanofi SA and partner Regeneron Pharmaceuticals Inc have started a clinical trial of their rheumatoid arthritis drug Kevzara as a treatment for the coronavirus, the companies said on Monday.

Enrolments for the mid-to-late stage trial will begin immediately, and the companies anticipate the trial will test up to 400 patients.

Kevzara is an infection-fighting protein known as monoclonal antibody.

Regeneron in February announced a partnership with the U.S. Department of Health and Human Services to develop a coronavirus treatment, and had said it would focus on monoclonal antibodies.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....